Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.
Inomata M, Kawashima Y, Saito R, Morinaga D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D, Yoshimura N, Harada T, Miyauchi E.
Inomata M, et al. Among authors: suzuki y.
Cancer Diagn Progn. 2024 Jul 3;4(4):515-520. doi: 10.21873/cdp.10357. eCollection 2024 Jul-Aug.
Cancer Diagn Progn. 2024.
PMID: 38962552
Free PMC article.